Xiayi Li, Chairman and CEO of Megamology Ophthalmology (06622.HK), said China's eye drug market will usher in a period of rapid growth in the next decade, with low treatment rates for degenerative macular disease and dry eye disease.

The company expects to launch three generic drugs by 2022 and plans to submit simplified new drug applications for nine generic candidates in the next three years. He revealed that generic drugs for glaucoma treatment are expected to be approved by the end of this year and commercialized as soon as next year.

CFO Feng Xinyan expects that generic drugs will start to generate revenue after commercialization of generic drugs. However, because of the lower price of generic drugs, the financial level will only have a fundamental turning point after the commercialization of innovative drugs.

With the introduction of Singapore government investment firm, Goldfield, TPG, Aobo Capital and Aobo Capital and Aer Eye Hospital, she said she would explore collaboration possibilities in R&D and commercialization.